Belluscura PLC Third US Distribution Agreement
13 Julho 2021 - 3:00AM
RNS Non-Regulatory
TIDMBELL
Belluscura PLC
13 July 2021
Belluscura PLC
("Belluscura" or the "Company" or "Group")
Third US Distribution Agreement
LONDON, U.K. AND PLANO, TX, U.S. (13 July 2021). Belluscura plc
(AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology , announces
the signing of its third distribution agreement and first agreement
with a durable medical equipment ("DME") provider, for its X-PLO(2)
R(TM) portable oxygen concentrator ("POC") portfolio. This is the
next stage in establishing US-wide distribution coverage as part of
the Group's commercialisation strategy.
The provider, a DME located in the upper Midwest US, has
multiple stores in several states and an online store. The
distributor issued its first purchase order with anticipated
delivery of the X-PLO(2) R(TM) portable oxygen concentrator
expected in less than ninety days.
As described in the Company's Admission Document, Belluscura's
plan is to appoint distributors in the US to give US-wide coverage
for the launch of the X-PLO(2) R(TM); and this is expected to occur
in the second half of 2021 and into 2022.
About the X-PLO R(TM)
The X-PLO R(TM) weighs less than 1.5kg (3.25lbs) and the
Directors believe it is the world's first modular portable oxygen
concentrator and that it will generate more oxygen by weight than
any other US Food & Drug Administration ("FDA") cleared POC in
its class. The X-PLO(2) R (TM) can deliver up to 95% pure oxygen to
patients 24 hours a day, 7 days a week to help improve the quality
of life for millions of people worldwide who suffer from chronic
lung diseases, such as Chronic Obstructive Pulmonary Disease and
respiratory distress caused by COVID-19. The X-PLO R (TM) is
designed to replace larger, metal oxygen tanks and heavier portable
oxygen concentrator devices.
In March 2021 Belluscura received 510(k) clearance from the FDA
for the X-PLO(2) R(TM), which will be launched commercially in Q3
2021. Additional products within the range will be launched within
the next 12 months.
Robert Rauker, CEO of Belluscura plc, said: "Having the X-PLO(2)
R(TM) portable oxygen concentrator available in stores for
potential customers to hold and feel, we believe, will help drive
sales of the units. We look forward to commercial launch which we
anticipate to start in just a few months."
For further information please contact:
Belluscura plc www.belluscura.com
Robert Rauker, Chief Executive via Walbrook PR
Officer
Anthony Dyer, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
Relations)
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502
558 258
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing
oxygen enrichment technology spanning broad industries and
therapies. Our innovative oxygen technologies are designed with a
global purpose: to create improved health and economic outcomes for
the patients, healthcare providers and insurance organisations.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases such as
marketing messages, corporate and product information into the
public domain. An RNS Regulatory announcement is required to be
notified under the AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABLLFFFDLLBBV
(END) Dow Jones Newswires
July 13, 2021 02:00 ET (06:00 GMT)
Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024